Free Preview — Investor scores & financials for RMD. Sign up for full buy targets.
Start Free

Is ResMed Inc. (RMD) Undervalued? Valuation & Fair Price

At $222.08, the frameworks are split on ResMed Inc. today — Warren Buffett rates it Buy, Phil Town (Rule #1) rates it Avoid, and Benjamin Graham and Peter Lynch rate it Hold. Each model calculates its own fair value and margin of safety; create a free account to see the exact buy price behind every verdict.

RM

ResMed Inc.

RMD

Healthcare · Medical - Devices · NYSE

$222.08

P/E 21.6×

CEO

Michael J. Farrell

Sector

Healthcare

Industry

Medical - Devices

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

Investor scorecard

How the four investors rate ResMed Inc.

A split decision across the frameworks

Warren Buffett
89%Strong Buy
Benjamin Graham
71%Hold
Peter Lynch
72%Hold
Phil Town (Rule #1)
82%Avoid

Investor model analysis

Details locked

At $222.08, 2 of 4 frameworks say Hold

Business Quality79/100

Intrinsic Value (DCF)

Warren Buffett's valuation model · select an investor above to switch

Intrinsic Value

Locked — upgrade to view

Buy Below

Locked — upgrade to view

Strong Buy

Locked — upgrade to view

Margin of Safety

Locked — upgrade to view

Unlock buy targets with a free account

Get started

Create a free account to see buy targets, full checklists & risk analysis Get started

Insider & congress activity

Are insiders buying RMD?

Over recent SEC Form 4 filings, RMD insiders bought $0 and sold $26.5M of stock across 34 open-market trades. Insiders sell for many reasons, but they buy for one.

Bought $0Sold $26.5M
Recent open-market insider trades for RMD
InsiderActionSharesValueDate
Farrell Michael J.Chairman and CEOSell4,991$1.1MSep 8, 2026
FARRELL PETER CdirectorSell970$228KSep 2, 2026
Farrell Michael J.Chairman and CEOSell4,991$1.0MAug 7, 2026
FARRELL PETER CdirectorSell8,000$1.8MAug 5, 2026
Farrell Michael J.Chairman and CEOSell4,991$1.1MJul 7, 2026

Members of Congress have also reported 38 trades in RMD. See the full insider & congress timeline.

Source: SEC Form 4 filings. Open-market buys & sells only. Not investment advice.

See the interactive insider chart & every trade

Scenario analysis

Bear, base & bull

Three growth assumptions, three fair values — and where today's price lands

What's working

Key strengths

Identified by Buffett framework analysis

Return on Equity

ROE Consistency

ROE Quality (Low Leverage)

Risk factors & concerns — free account

Unlock

Company financials

5-Year Financials

Income statement highlights — annual, USD

Metric20262025202420232022
Revenue$5.7B
$5.1B
$4.7B
$4.2B
$3.6B
Rev. Growth+9.9%+9.8%+10.9%+18.0%—
Net Income$1.5B$1.4B$1.0B$898M$779M
Net Margin26.9%27.2%21.8%21.3%21.8%
EPS (Diluted)$10.44$9.55$6.94$6.12$5.34
Free Cash FlowLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to viewLocked — upgrade to view

Full analysis included

See the complete picture for RMD

Exact buy targets, margin of safety, detailed investor checklists, and risk breakdown — all frameworks, all numbers.

Buy & sell targetsFull checklistRisk breakdown

Free: 3 analyses/month · Pay per stock: $4.99 · Pro: $19.99/mo

More Healthcare stocks

Educational Use Only · Not Financial Advice

Analysis, scores, valuations, and buy zones are derived from publicly documented investor frameworks (Buffett, Lynch, Benjamin Graham, Phil Town) for learning purposes only. They are not recommendations from licensed financial advisors. Past performance does not guarantee future results. Prices may be delayed up to 15 minutes. Always conduct your own research before making any investment decisions.